LeyoMyosarcomas Avanzados . Ensayo Clínico Combinatorio entre Pazopanib Más Gemcitabina . Resultados .

El Estudio LMS03 " No Logró Cumplir su Objetivo Principal ", pero es casi positivo cuando se consideran los Resultados por Protocolo con una mediana de SLP de 7,1 meses. 

Inacceptable and promising 9-month PFS rates were defined, in the intent-to-treat population, as 32% and 44%. ...

********************************

Resultados con Yondelis :

Link : https://www.practiceupdate.com/content/trabectedin-or-dacarbazine-in-patients-with-advanced-liposarcoma-or-leiomyosarcoma/85007

This is a randomized phase III study of trabectedin (n = 384) versus dacarbazine (n = 193) in previously-treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). At the time of the final overall survival analysis, 577 patients had been assigned randomly, including 423 (73%) with LMS and 154 (27%) with LPS. The authors found that overall survival was comparable between LPS/LMS patients receiving trabectedin or dacarbazine, which is consistent with the interim analysis results.

Improved disease control with trabectedin was observed in both LPS and LMS.

– Jeffrey Wiisanen, MD